한글목차

광선각화증 치료 동향 및 전망

세계 광선각화증 치료 시장의 미래는 병원, 개인 클리닉 및 재택 치료 시장에서의 기회로 인해 유망합니다. 세계 광선각화증 치료 시장은 2024년부터 2030년까지 7.0%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년까지 약 93억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 광선각화증 유병률 증가와 노인 인구 증가입니다.

• Lucintel의 예측에 따르면, 치료 분야에서는 광선각화증 치료에 대한 냉동 요법의 채택이 증가함에 따라 예측 기간 동안 외과 수술이 가장 큰 분야가 될 것으로 예상됩니다.
• 용도별로는 병원에서의 광역학 치료 증가로 인해 최종 용도가 가장 큰 부문을 차지할 것으로 보입니다.
• 지역별로는 북미가 예측 기간 동안 가장 규모가 큰 지역으로 남을 것으로 보입니다. 이는 광 역학 치료의 보급률 증가, 정부의 적극적인 노력, 소비자 인식 증가, 의료 인프라 강화에 기인합니다.

광선각화증 치료제 시장의 전략적 성장 기회

AK 치료 시장에는 다음과 같은 성장 기회가 있습니다.

1. 치료법의 발전: 보다 효과적인 치료법에 대한 수요는 첨단 외용제, 개선된 PDT, 획기적인 레이저 치료의 개발을 촉진하고 있습니다. 이러한 기술 혁신은 환자에게 더 나은 결과를 가져다주고 시장 성장을 가속할 것입니다.

2. 신흥 시장 확대: 중국, 인도, 브라질 등 신흥 시장의 의료 인프라가 빠르게 개선되고 있어 AK 치료 확대 기회를 창출하고 있습니다. 이들 지역에서는 첨단 의료에 대한 수요가 증가하고 있어 큰 시장 잠재력을 가지고 있습니다.

3. 전문 치료: 우수한 침투성, 부작용 최소화 등 특정 환자의 요구에 맞게 설계된 치료법이 틈새 시장에서 인기를 끌면서 새로운 성장 기회를 창출하고 있습니다.

4. 디지털 헬스 솔루션: 원격 의료 플랫폼과 AI 기반 진단 도구를 치료 과정에 통합하여 질병 관리를 강화하고 환자 참여와 결과를 개선할 수 있습니다. 이러한 디지털 헬스 통합은 보다 종합적인 치료의 기회를 창출합니다.

5. 전략적 파트너십: 제약회사, 의료기기 제조업체, 의료 서비스 제공업체의 협력은 혁신과 시장 확대를 촉진하고 있습니다. 파트너십은 새로운 제품 개발로 이어져 시장 확대에 기여합니다.

광선각화증 치료제 시장 성장 촉진요인 및 과제

AK 치료 시장은 몇 가지 요인에 의해 주도되고 있지만 지속적인 성장을 위해 해결해야 할 과제에 직면하고 있습니다.

촉진요인

1. 기술 발전: 첨단 PDT 및 레이저 치료의 개발로 치료 효과가 향상되어 환자와 의료 서비스 제공업체 사이에서 이러한 선택이 점점 더 인기를 얻고 있습니다.

2. 광선각화증 발생률 증가: 일광화상, 고령화 등의 요인으로 인해 AK의 발병률이 증가함에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다.

3. 규제 지원: 새로운 치료법의 승인을 지원하는 규제 프레임워크는 혁신적인 치료법 시장 진입을 가속화하고 있습니다.

4. 인식 증가: AK의 위험, 특히 일광화상별 위험에 대한 사회적 인식이 높아짐에 따라 조기 발견이 가능해져 치료를 원하는 환자가 증가하고 있습니다.

5.경제 성장: 신흥 시장의 경제 성장으로 의료비 지출이 증가하여 AK의 최신 치료법에 대한 접근성이 향상되고 있습니다.

과제:

1. 고가의 치료비: PDT, 레이저 치료와 같은 고급 치료는 고가의 비용이 들기 때문에 일부 환자, 특히 저소득층 환자의 경우 치료 접근성이 제한될 수 있습니다.

2. 부작용: 치료방법에 따라 부작용이 발생할 수 있으며, 이는 보급 및 환자 수용성에 영향을 미칠 수 있습니다.

3. 규제 장애물: 규제 당국의 승인을 받는 데는 많은 시간과 비용이 소요되기 때문에 새로운 치료법의 출현을 지연시키고 혁신적인 치료법 시장 진입을 제한할 수 있습니다.

주요 지역에서는 AK 치료 시장이 크게 발전하고 있습니다.

• 미국: 미국은 AK에 대한 병용요법 및 첨단 치료의 도입에 있어 선도적인 역할을 하고 있으며, FDA의 신약 승인과 현재 진행 중인 면역조절제 임상시험을 통해 새로운 치료 옵션을 기대할 수 있게 되었습니다.
• 중국: 중국에서는 PDT의 인기가 높아지고 있으며, 현지 제약사들은 비용 효율적인 치료법을 개발하기 위해 연구개발에 투자하고 있습니다. 국제 기업과의 제휴를 통해 새로운 치료법에 대한 접근성도 향상되고 있습니다.
• 독일: 독일은 분수 레이저를 사용하여 전암세포를 표적으로 삼아 치료 속도를 높이고 합병증 위험을 줄이는데 앞장서고 있습니다. 독일의 규제적 지원은 AK 치료의 기술 혁신을 촉진하고 있습니다.
• 인도: 인도는 제네릭 의약품과 정부 보조금을 통해 저렴한 가격으로 AK 치료를 받을 수 있도록 하는 데 주력하고 있습니다. 국민들의 인식이 높아지면서 피부과에서 치료를 받으려는 환자들이 증가하고 있습니다.
• 일본: 일본은 고해상도 피부단층촬영, AI 기반 진단 도구 등 첨단 영상진단 기술을 선도하며 AK의 진단 및 치료 성적을 크게 향상시키고 있습니다.

목차

제1장 주요 요약

제2장 세계의 광선각화증 치료 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 광선각화증 치료 시장 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 광선각화증 치료 시장, 치료법별
  • 외용 요법
  • 광선 역학 요법
  • 수술
• 세계의 광선각화증 치료 시장, 약제 클래스별
  • 뉴클레오티드 대사 억제제
  • NSAIDs
  • 면역반응 조절제
  • 광증강제
  • 기타
• 세계의 광선각화증 치료 시장, 최종 용도별
  • 병원
  • 개인 클리닉
  • 홈케어
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018-2023년)

• 지역별 세계의 광선각화증 치료 시장
• 북미의 광선각화증 치료 시장
• 유럽의 광선각화증 치료 시장
• 아시아태평양의 광선각화증 치료 시장
• 기타 지역의 광선각화증 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• h4orter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 치료법별 세계의 광선각화증 치료 시장 성장 기회
  • 약제 클래스별 세계의 광선각화증 치료 시장 성장 기회
  • 최종 용도별 세계의 광선각화증 치료 시장 성장 기회
  • 지역별 세계의 광선각화증 치료 시장 성장 기회
• 세계의 광선각화증 치료 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 광선각화증 치료 시장 능력 확대
  • 세계 광선각화증 치료 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Almirall
• LEO Pharma
• Sun Pharmaceutical Industries
• Novartis
• GALDERMA
• Ortho Dermatologics
• BIOFRONTERA

영문목차

Actinic Keratosis Treatment Trends and Forecast

The future of the global actinic keratosis treatment market looks promising with opportunities in the hospital, private clinic, and homecare markets. The global actinic keratosis treatment market is expected to reach an estimated $9.3 billion by 2030 with a CAGR of 7.0% from 2024 to 2030. The major drivers for this market are the increasing incidence of actinic keratosis and the rising elderly population.

• Lucintel forecasts that, within the therapy category, surgery will remain the largest segment over the forecast period due to the increased adoption of cryotherapy for treating actinic keratosis.
• Within the application category, end-use will remain the largest segment due to an increase in photodynamic therapy procedures performed in hospitals.
• In terms of regions, North America will remain the largest region over the forecast period due to the increasing prevalence of actinic keratosis, positive government initiatives, growing consumer awareness, and enhancements in healthcare infrastructure.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Actinic Keratosis Treatment Market

The treatment of actinic keratosis (AK) is evolving rapidly due to the emergence of non-invasive therapies, combination treatments, and personalized approaches. These trends are reshaping how AK is diagnosed and managed, leading to better patient outcomes.

1. Non-Invasive Treatments: Non-invasive therapies such as Photodynamic Therapy (PDT) and laser treatments (e.g., fractional laser resurfacing) are gaining popularity due to their effectiveness, minimal pain, and shorter recovery times. These methods are preferred by both patients and healthcare providers because they offer comfort and convenience with reduced downtime.

2. Combination Therapies: Combining topical agents with PDT or laser treatments is becoming a common practice. This approach improves treatment efficiency, reduces recurrence rates, and provides a more holistic approach to managing AK on an individual basis, rather than relying on a one-size-fits-all treatment.

3. Personalized Medicine: Advances in genetic research and diagnostic technologies are leading to more personalized treatment plans for AK. By tailoring treatments to individual patient profiles, outcomes are improved, and side effects are minimized, resulting in higher patient satisfaction.

4. AI and Imaging Technologies: The integration of AI-powered diagnostics and advanced imaging technologies has revolutionized early detection and monitoring of AK. AI helps dermatologists make more accurate assessments, facilitating timely intervention and improved treatment outcomes.

5. Prevention Focus: Public awareness of sun protection and early intervention is on the rise. Educational campaigns and the availability of protective skincare products are key factors in preventing the development of AK, promoting earlier treatment, and reducing the incidence of this skin condition.

These emerging trends are driving a transformation in the AK treatment landscape, focusing on more effective, patient-centered care.

Recent Developments in the Actinic Keratosis Treatment Market

Recent innovations in the AK treatment market focus on improving efficacy, patient comfort, and accessibility. Some key developments include:

1. New Topical Agents: The development of novel topical treatments with better skin penetration and reduced side effects has enhanced patient outcomes. These agents use advanced drug delivery systems for more prolonged action.

2. Advanced Photodynamic Therapy (PDT): Innovations in PDT, such as better photosensitizers and improved light delivery mechanisms, are making PDT more effective and comfortable, resulting in higher success rates.

3. Laser Treatment Advancements: The development of fractional laser technologies has improved AK treatment by targeting specific areas, reducing healing time, and minimizing complications. These lasers are now widely used in dermatology for their non-invasive nature.

4. AI Integration in Diagnostics: AI is transforming how AK is diagnosed and monitored. AI-based diagnostic tools offer accurate assessments, allowing dermatologists to plan treatments more effectively, leading to better patient outcomes.

5. Regulatory Approvals: Recent regulatory approvals have paved the way for new, advanced treatments to enter the market. These approvals are crucial for ensuring the availability of safe and effective therapies for AK.

Strategic Growth Opportunities for Actinic Keratosis Treatment Market

The AK treatment market offers several avenues for growth, including:

1. Treatment Modalities Advancements: The demand for more effective treatments is driving the development of advanced topical agents, improved PDT, and groundbreaking laser therapies. These innovations promise better outcomes for patients and fuel market growth.

2. Emerging Markets Expansion: The healthcare infrastructure in emerging markets such as China, India, and Brazil is rapidly improving, creating opportunities for the expansion of AK treatments. Growing demand for advanced medical treatments in these regions offers significant market potential.

3. Specialized Treatments: Tailored treatments designed to meet specific patient needs, such as those with superior penetration or minimal side effects, are gaining popularity in niche markets, providing new growth opportunities.

4. Digital Health Solutions: Integrating telemedicine platforms and AI-powered diagnostic tools into the treatment process can enhance disease management, improving patient engagement and outcomes. This digital health integration opens up opportunities for more comprehensive care.

5. Strategic Partnerships: Collaborations between pharmaceutical companies, medical device manufacturers, and healthcare providers are driving innovation and market expansion. Partnerships can lead to the development of new products and help expand market reach.

Actinic Keratosis Treatment Market Driver and Challenges

The AK treatment market is driven by several factors, but faces challenges that must be addressed for sustained growth:

Drivers:

1. Technological Advancements: The development of advanced PDT and laser therapies has improved treatment efficacy, making these options increasingly popular among patients and healthcare providers.

2. Rising Incidence of Actinic Keratosis: The growing incidence of AK, fueled by factors such as sun exposure and an aging population, has created a greater demand for effective treatments.

3. Regulatory Support: Regulatory frameworks that support the approval of new treatments have accelerated the entry of innovative therapies into the market.

4. Rising Awareness: Increased public awareness about the risks of AK, particularly due to sun exposure, has led to earlier detection and more patients seeking treatment.

5. Economic Growth: The economic expansion of emerging markets has increased healthcare spending, providing greater access to modern treatments for AK.

Challenges:

1. High Treatment Costs: The high cost of advanced treatments, such as PDT and laser therapies, may limit access for some patients, particularly in lower-income regions.

2. Side Effects: Some treatments may cause undesirable side effects, which could impact their widespread adoption and patient acceptability.

3. Regulatory Hurdles: The lengthy and expensive process of obtaining regulatory approvals can delay the availability of new treatments and limit market access for innovative therapies.

Key regions are seeing significant developments in the AK treatment market:

• United States: The U.S. is a leader in the adoption of combination therapies and advanced treatments for AK. FDA approvals for new drugs and ongoing clinical trials into immune modulators promise new treatment options.
• China: In China, PDT has become increasingly popular, and local pharmaceutical companies are investing in research and development to create cost-effective treatments. Collaborations with international firms are improving access to novel therapies.
• Germany: Germany leads in the use of fractional laser technologies, which target pre-cancerous cells for faster healing and reduced complication risks. Regulatory support in Germany fosters innovation in AK treatment.
• India: India focuses on making AK treatments affordable and accessible through generic drugs and government subsidies. Increasing public awareness has led to more patients seeking dermatological care.
• Japan: Japan is at the forefront of advanced imaging technologies, such as high-resolution dermoscopy and AI-based diagnostic tools, which have significantly improved AK diagnosis and treatment outcomes.

List of Actinic Keratosis Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies actinic keratosis treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the actinic keratosis treatment companies profiled in this report include-

• Almirall
• LEO Pharma
• Sun Pharmaceutical Industries
• Novartis
• GALDERMA
• Ortho Dermatologics
• BIOFRONTERA

Actinic Keratosis Treatment by Segment

The study includes a forecast for the global actinic keratosis treatment by therapy, drug class, end use, and region.

Actinic Keratosis Treatment Market by Therapy [Analysis by Value from 2018 to 2030]:

• Topical
• Photodynamic Therapy
• Surgery

Actinic Keratosis Treatment Market by Drug Class [Analysis by Value from 2018 to 2030]:

• Nucleoside Metabolic Inhibitor
• NSAIDs
• Immune Response Modifiers
• Photoenhancers
• Others

Actinic Keratosis Treatment Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Private Clinics
• Homecare
• Others

Actinic Keratosis Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Actinic Keratosis Treatment Market

• United States: The U.S. is a leader in the adoption of combination therapies and advanced treatments for AK. FDA approvals for new drugs and ongoing clinical trials into immune modulators promise new treatment options.
• China: In China, PDT has become increasingly popular, and local pharmaceutical companies are investing in research and development to create cost-effective treatments. Collaborations with international firms are improving access to novel therapies.
• Germany: Germany leads in the use of fractional laser technologies, which target pre-cancerous cells for faster healing and reduced complication risks. Regulatory support in Germany fosters innovation in AK treatment.
• India: India focuses on making AK treatments affordable and accessible through generic drugs and government subsidies. Increasing public awareness has led to more patients seeking dermatological care.
• Japan: Japan is at the forefront of advanced imaging technologies, such as high-resolution dermoscopy and AI-based diagnostic tools, which have significantly improved AK diagnosis and treatment outcomes.

Features of the Global Actinic Keratosis Treatment Market

Market Size Estimates: Actinic keratosis treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Actinic keratosis treatment market size by therapy, drug class, end use, and region in terms of value ($B).

Regional Analysis: Actinic keratosis treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy, drug class, end use, and regions for the actinic keratosis treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the actinic keratosis treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the actinic keratosis treatment market by therapy (topical, photodynamic therapy, and surgery), drug class (nucleoside metabolic inhibitor, NSAIDs, immune response modifiers, photoenhancers, and others), end use (hospitals, private clinics, homecare, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Actinic Keratosis Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Actinic Keratosis Treatment Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Actinic Keratosis Treatment Market by Therapy
  • 3.3.1: Topical
  • 3.3.2: Photodynamic Therapy
  • 3.3.3: Surgery
• 3.4: Global Actinic Keratosis Treatment Market by Drug Class
  • 3.4.1: Nucleoside Metabolic Inhibitor
  • 3.4.2: NSAIDs
  • 3.4.3: Immune Response Modifiers
  • 3.4.4: Photoenhancers
  • 3.4.5: Others
• 3.5: Global Actinic Keratosis Treatment Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Private Clinics
  • 3.5.3: Homecare
  • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Actinic Keratosis Treatment Market by Region
• 4.2: North American Actinic Keratosis Treatment Market
  • 4.2.1: North American Market by Therapy: Topical, Photodynamic Therapy, and Surgery
  • 4.2.2: North American Market by End Use: Hospitals, Private Clinics, Homecare, and Others
• 4.3: European Actinic Keratosis Treatment Market
  • 4.3.1: European Market by Therapy: Topical, Photodynamic Therapy, and Surgery
  • 4.3.2: European Market by End Use: Hospitals, Private Clinics, Homecare, and Others
• 4.4: APAC Actinic Keratosis Treatment Market
  • 4.4.1: APAC Market by Therapy: Topical, Photodynamic Therapy, and Surgery
  • 4.4.2: APAC Market by End Use: Hospitals, Private Clinics, Homecare, and Others
• 4.5: ROW Actinic Keratosis Treatment Market
  • 4.5.1: ROW Market by Therapy: Topical, Photodynamic Therapy, and Surgery
  • 4.5.2: ROW Market by End Use: Hospitals, Private Clinics, Homecare, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Actinic Keratosis Treatment Market by Therapy
  • 6.1.2: Growth Opportunities for the Global Actinic Keratosis Treatment Market by Drug Class
  • 6.1.3: Growth Opportunities for the Global Actinic Keratosis Treatment Market by End Use
  • 6.1.4: Growth Opportunities for the Global Actinic Keratosis Treatment Market by Region
• 6.2: Emerging Trends in the Global Actinic Keratosis Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Actinic Keratosis Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Actinic Keratosis Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Almirall
• 7.2: LEO Pharma
• 7.3: Sun Pharmaceutical Industries
• 7.4: Novartis
• 7.5: GALDERMA
• 7.6: Ortho Dermatologics
• 7.7: BIOFRONTERA